BACKGROUND PŘEDMĚT A ÚČEL SMLOUVY Sample Clauses

BACKGROUND PŘEDMĚT A ÚČEL SMLOUVY. 1.1 ICON is a clinical research organization principally engaged in the design, set-up and management of human clinical trials, and other related services, on behalf of the producers of pharmaceutical products. ICON je smluvní výzkumná organizace, jejíž hlavní činností je navrhování, zahájení a řízení klinických hodnocení u lidských subjektů a poskytování dalších souvisejících služeb pro výrobce farmaceutických přípravků. 1.2 ICON’S client, CSL Behring LLC (CSLB), 0000 Xxxxx Xxxxxx, Xxxx xx Xxxxxxx, Xxxxxxxxxxxx, XXX (hereinafter known as the “Sponsor”) is developing an investigational product called Clazakizumab (hereinafter called the “Investigational Product”) for use in patients with Treatment of CABMR in kidney transplant recipients (hereinafter called the “Study Indication”) and the Sponsor has retained ICON to conduct certain services in relation to the Study under separate contract including without limitation contracting with clinical research sites. Klient společnosti ICON, společnost CSL Behring LLC (CSLB), 0000 Xxxxx Xxxxxx, Xxxx xx Xxxxxxx, Xxxxxxxxxxxx, XXX (dále jen „zadavatel“) vyvíjí hodnocené léčivo s názvem clazakizumab (dále jen „hodnocené léčivo”) za účelem aplikace u pacientů k léčbě CABMR u příjemců transplantované ledviny (dále jen „indikace, která je předmětem klinického hodnocení“), a zadavatel využívá společnost ICON k poskytování některých služeb v souvislosti s klinickým hodnocením v rámci samostatné smlouvy, a to mimo jiné pro uzavírání smluv s klinickými výzkumnými pracovišti. 1.3 The Institution and its staff, including without limitation the Investigator, are experienced in the evaluation and treatment of patients with Study Indication. Zdravotnické zařízení a jeho zaměstnanci, mimo jiné včetně zkoušejícího, mají zkušenosti s hodnocením a léčbou pacientů s indikací, která je předmětem klinického hodnocení. 1.4 ICON wishes to engage the Investigator to conduct a clinical study to evaluate the Investigational Product, and the Institution/Investigator wishes to conduct such a clinical study. Společnost ICON si přeje využívat služby zkoušejícího k provedení klinického hodnocení za účelem vyhodnocení hodnoceného léčiva a zdravotnické zařízení / zkoušející si přeje toto klinické hodnocení provést. 1.5 The Institution has agreed to the participation of the Investigator in carrying out the said clinical study on its behalf. Zdravotnické zařízení souhlasí s účastí zkoušejícího na provádění výše uvedeného klinického hodnocení jménem ...
Sample 1See All (7)
AutoNDA by SimpleDocs
BACKGROUND PŘEDMĚT A ÚČEL SMLOUVY. 1.1 Sponsor is a pharmaceutical company principally engaged in the design, set-up and management of human clinical trials, among other activities. Zadavatel je farmaceutická společnost, jejíž hlavní činností je mezi jinými navrhování, zahájení a řízení klinických hodnocení u lidských subjektů.
Sample 1
BACKGROUND PŘEDMĚT A ÚČEL SMLOUVY. 1.1 CRO is a Contract Research Organization whose primary activity is the setup and management of human clinical trials and other related services, on behalf of the owners and/or manufacturers of pharmaceutical products. 1.1 CRO je smluvní výzkumná organizace, jejíž hlavní činností je navrhování a řízení klinických hodnocení týkajících se lidského subjektu a poskytování dalších souvisejících služeb pro majitele a/nebo výrobce farmaceutických produktů. 1.2 CRO is acting on behalf of its client, Pharmacyclics LLC (“Sponsor”) to set up and manage the Study involving the Investigational Product(s), and concerning the design, funding, and administration of such Study. Sponsor is 1.2 CRO jednající jménem svého klienta Pharmacyclics LLC („Zadavatel“) nastavit a řídit Klinické hodnocení zahrnující Hodnocené léčivo (a) a týkající se dizajnu, financování a správy tohoto Klinického hodnocení. Zadavatel je an intended third party beneficiary of this Agreement. oprávněnou třetí stranou této Smlouvy. 1.3 The Institution and its staff, including without limitation the Investigator, are experienced in the evaluation and treatment of patients with Follicular Lymphoma.
Sample 1
BACKGROUND PŘEDMĚT A ÚČEL SMLOUVY. 1.1 Sponsor is a pharmaceutical company principally engaged in the design, set-up and management of human clinical trials among other activities. Zadavatel je farmaceutická společnost, jejíž hlavní činností je mimo jiné navrhování, zahájení a řízení klinických hodnocení u lidských subjektů. 1.2 Sponsor is developing an investigational product called CR845 (hereinafter called the “Investigational Product”) for use in patients with Moderate-to-Severe Pruritus (hereinafter called the “Study Indication”). Zadavatel vyvíjí hodnocené léčivo s názvem CR845 (dále jen „hodnocené léčivo”) za účelem aplikace u pacientů se středně těžkým až těžkým pruritem (dále jen „indikace, která je předmětem klinického hodnocení“). 1.3 SPONSOR has engaged, pursuant to a separate contract, ICON Clinical Research Limited (“CRO”), having an address at South County Business Park, Leopardstown, Dublin 18, Ireland, to act as contract research organization in managing, coordinating and carrying out some SPONSOR’s responsibilities in connection with the Study contemplated by this Agreement, including but not limited to those V samostatné smlouvě pověřil Zadavatel společnost ICON Clinical Research Limited („CRO“), se sídlem na adrese South County Business Park, Leopardstown, Dublin 18, Irsko, jako smluvní výzkumnou organizaci správou, koordinací a provedením některých povinností zadavatele v souvislosti s klinickým hodnocením, na které se vztahuje tatosmlouva, včetně mimo jiné plateb, podání a komunikace s regulančními orgány, zůstává však nadále odpovědnou stranou v rámci této smlouvy. relating to payments, regulatory submissions, and communications but shall remain the liable party under this Agreement. 1.4 As Sponsor is located outside the European Union and outside the European Economic Area, it therefore appoints ICON (LR) Limited (represented by Xxxxxx Xxxxx), with an address at South County Business Park, Leopardstown, Dublin 18, Ireland as legal representative in the EU. Protože se zadavatel nachází mimo Evropskou unii a mimo Evropský hospodářský prostor, jmenuje společnost ICON (LR) Limited (zastupovanou Xxxxxx Xxxxx se sídlem na adrese South County Business Park, Leopardstown, Dublin 18, Irsko zákonným zástupcem v EU. 1.5 The Institution and its staff, including without limitation with a place of business at Nemocnice Nové Město na Moravě, p.o., Interní oddělení, Žďárská 000, 000 00 Xxxx Xxxxx xx Xxxxxx, Xxxxx Xxxxxxxx, (hereinafter called the“Investigator)”, are experienced in t...
Sample 1
BACKGROUND PŘEDMĚT A ÚČEL SMLOUVY. 1.1 ICON is a clinical research organization principally engaged in the design, set-up and management of human clinical trials, and other related services, on behalf of the producers of pharmaceutical products. ICON je smluvní výzkumná organizace, jejíž hlavní činností je navrhování, zahájení a řízení klinických hodnocení u lidských subjektů a poskytování dalších souvisejících služeb pro výrobce farmaceutických přípravků.
Sample 1

Related to BACKGROUND PŘEDMĚT A ÚČEL SMLOUVY

  • Background Screening VENDOR shall comply with all requirements of Sections 1012.32 and 1012.465, Florida Statutes, and all of its personnel who (1) are to be permitted access to school grounds when students are present, (2) will have direct contact with students, or (3) have access or control of school funds, will successfully complete the background screening required by the referenced statutes and meet the standards established by the statutes. This background screening will be conducted by SBBC in advance of VENDOR or its personnel providing any services under the conditions described in the previous sentence. VENDOR shall bear the cost of acquiring the background screening required by Section 1012.32, Florida Statutes, and any fee imposed by the Florida Department of Law Enforcement to maintain the fingerprints provided with respect to VENDOR and its personnel. The parties agree that the failure of VENDOR to perform any of the duties described in this section shall constitute a material breach of this Agreement entitling SBBC to terminate immediately with no further responsibilities or duties to perform under this Agreement. VENDOR agrees to indemnify and hold harmless SBBC, its officers and employees from any liability in the form of physical or mental injury, death or property damage resulting from VENDOR’s failure to comply with the requirements of this section or with Sections 1012.32 and 1012.465, Florida Statutes.

  • TECHNOLOGY/KNOWLEDGE TRANSFER ACTIVITIES The goal of this task is to develop a plan to make the knowledge gained, experimental results, and lessons learned available to the public and key decision makers. • Prepare an Initial Fact Sheet at start of the project that describes the project. Use the format provided by the CAM. • Prepare a Final Project Fact Sheet at the project’s conclusion that discusses results. Use the format provided by the CAM. • Prepare a Technology/Knowledge Transfer Plan that includes: o An explanation of how the knowledge gained from the project will be made available to the public, including the targeted market sector and potential outreach to end users, utilities, regulatory agencies, and others. o A description of the intended use(s) for and users of the project results. o Published documents, including date, title, and periodical name. o Copies of documents, fact sheets, journal articles, press releases, and other documents prepared for public dissemination. These documents must include the Legal Notice required in the terms and conditions. Indicate where and when the documents were disseminated. o A discussion of policy development. State if project has been or will be cited in government policy publications, or used to inform regulatory bodies. o The number of website downloads or public requests for project results. o Additional areas as determined by the CAM. • Conduct technology transfer activities in accordance with the Technology/Knowledge Transfer Plan. These activities will be reported in the Progress Reports. • When directed by the CAM, develop Presentation Materials for an Energy Commission- sponsored conference/workshop(s) on the project. • When directed by the CAM, participate in annual EPIC symposium(s) sponsored by the California Energy Commission. • Provide at least (6) six High Quality Digital Photographs (minimum resolution of 1300x500 pixels in landscape ratio) of pre and post technology installation at the project sites or related project photographs. • Prepare a Technology/Knowledge Transfer Report on technology transfer activities conducted during the project. • Initial Fact Sheet (draft and final) • Final Project Fact Sheet (draft and final) • Presentation Materials (draft and final) • High Quality Digital Photographs • Technology/Knowledge Transfer Plan (draft and final) • Technology/Knowledge Transfer Report (draft and final)

  • General Background (Brief description of the national, sector-specific or other relevant context in which the individual contractor will operate)

  • Xxxxx, Haldimand, Norfolk An employee shall be granted five working days bereavement leave with pay upon the death of the employee’s spouse, child, stepchild, parent, stepparent, legal guardian, grandchild or step-grandchild.

  • Přetrvající platnost This Section 3 “

  • Vlastnictví Zdravotnické zařízení si ponechá a bude uchovávat Zdravotní záznamy. Zdravotnické zařízení a Zkoušející převedou na Zadavatele veškerá svá práva, nároky a tituly, včetně práv duševního vlastnictví k Důvěrným informacím (ve smyslu níže uvedeném) a k jakýmkoli jiným Studijním datům a údajům.

  • Manufacturing Technology Transfer Upon AbbVie’s written request with respect to a given Collaboration CAR-T Product and Licensed Product, Caribou shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party Provider) of all Materials and Know-How Controlled by Caribou relating to the then-current process for the Manufacture of such Collaboration CAR-T Product and any corresponding Licensed Products (each, a “Manufacturing Process”). Caribou shall provide, shall cause its Affiliates to provide, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers to provide, all reasonable assistance requested by AbbVie to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to implement each Manufacturing Process at the facilities designated by AbbVie. If requested by AbbVie, such assistance shall include facilitating the entering into of agreements with applicable Third Party suppliers relating to such Collaboration CAR-T Product and any corresponding Licensed Products. Without limitation of the foregoing, in connection with the Manufacturing Process and related transfer: (a) Caribou shall, and shall cause its Affiliates to, make available to AbbVie (or its Affiliate or designated Third Party Provider, as applicable), and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers to make available to AbbVie, from time to time as AbbVie may request, all Materials and Manufacturing-related Know-How Controlled by Caribou relating to each Manufacturing Process, including methods, reagents and processes and testing/characterization Know-How, and all documentation constituting material support, performance advice, shop practice, standard operating procedures, specifications as to Materials to be used, and control methods, that are necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party manufacturer, as applicable) to use and practice such Manufacturing Process; (b) Caribou shall cause all appropriate employees and representatives of Caribou and its Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate employees and representatives of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) at the applicable manufacturing facility at mutually convenient times to assist with the working up and use of each Manufacturing Process and with the training of the personnel of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to the extent necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to use and practice such Manufacturing Process; (c) Without limiting the generality of this Section 4.4.2, Caribou shall cause all appropriate analytical and quality control laboratory employees and representatives of Caribou and its Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate analytical and quality control laboratory employees and representatives of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) at the applicable manufacturing facility and make available all necessary equipment, at mutually convenient times, to support and execute the provision of all applicable analytical methods and the validation thereof (including all applicable Know-How, Information and Materials Controlled by Caribou, and sufficient supplies of all primary and other reference standards); (d) Caribou shall, and shall cause its Affiliates to, take such steps, and shall use Commercially Reasonable Efforts to assist AbbVie in causing Third Party Providers take such steps, as are necessary or reasonably useful to assist AbbVie (or its Affiliate or designated Third Party Provider, as applicable) in obtaining any necessary licenses, permits or approvals from Regulatory Authorities with respect to the Manufacture of the applicable Collaboration CAR-T Products and corresponding Licensed Products at the applicable facilities; and (e) Caribou shall, and shall cause its Affiliates to, provide, and shall use Commercially Reasonable Efforts to assist AbbVie in causing Third Party Providers to provide, such other assistance as AbbVie (or its Affiliate or designated Third Party Provider, as applicable) may reasonably request to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to use and practice each Manufacturing Process and otherwise to Manufacture the applicable Collaboration CAR-T Products and corresponding Licensed Products.

  • Criminal Background Check It is the Responsibility of CHESAPEAKE CENTER, INC. to make certain that its employees, agents, volunteers, and contractors, who have contact with students receiving services are fingerprinted and have a background check in compliance with Family Law Article, Annotated Code of Maryland, and Section 5-551 through 5-557. CHESAPEAKE CENTER, INC. may not hire, contract, or otherwise engage an individual to participate in this Cooperative Agreement who has been convicted of a crime involving child abuse or neglect; contributing to the delinquency of a minor; a crime of violence as set forth in Criminal Law Article §14-101, Annotated Code of Maryland; or has evidence of a criminal history which in the opinion of Chesapeake Center, Inc. makes the individual unfit to participate in this Cooperative Agreement.

  • Background Check The Department or Customer may require the Contractor to conduct background checks of its employees, agents, representatives, and subcontractors as directed by the Department or Customer. The cost of the background checks will be borne by the Contractor. The Department or Customer may require the Contractor to exclude the Contractor’s employees, agents, representatives, or subcontractors based on the background check results. In addition, the Contractor must ensure that all persons have a responsibility to self-report to the Contractor within three (3) calendar days any arrest for any disqualifying offense. The Contractor must notify the Contract Manager within twenty-four (24) hours of all details concerning any reported arrest. Upon the request of the Department or Customer, the Contractor will re-screen any of its employees, agents, representatives, and subcontractors during the term of the Contract.

  • VOETSTOOTS The PROPERTY is sold: 8.1. Voetstoots in accordance with the Sectional Plan and the participation quota endorsed thereon with the opening of the Sectional Title Register, or as they are endorsed already, and any amendments or adjustments thereto from time to time in accordance with the terms of the Act and without any warranties express or implied, the SELLER shall not be liable for any patent or latent defects. Should the extent of the Section or of the PROPERTY differ from that which is contained in the title deed or sectional plan or any amendment thereto, the SELLER shall not be liable for any shortfall or be entitled to any compensation for any surplus. 8.2. Subject to all the conditions and Regulations of the Act. 8.3. The PURCHASER acknowledges that this is not a construction contract and that he is purchasing a completed unit. The PURCHASER shall not have the right to interfere in any way with the building operations of the SELLER’S employees. He shall also have no right to retention. This Clause is also applicable in the case of the bank holding back any retention amount out of its own accord or on request of the PURCHASER. 8.4. The SELLER undertakes to erect the unit according to the general building standards as set by Financial Institutions. The unit is be registered with the NHBRC. 8.5. Should a dispute arise or be declared, such dispute shall be resolved by an Arbitrator appointed by the Developer. The costs in respect thereof shall be borne by the unsuccessful party. Pending the outcome of the dispute, the PURCHASER shall be obliged to pay the outstanding amount to the Conveyancers who shall hold it in trust.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!